Advertisement
Screener

Xilio Therapeutics, Inc. (XLO) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Xilio Therapeutics, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Xilio Therapeutics, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $4.99M went out.
  • Fiscal year ended 2025-12-31: from investing, $518.00K went out.
  • Fiscal year ended 2025-12-31: from financing, $87.78M came in.
  • Fiscal year ended 2025-12-31: change in cash, $82.27M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDebt paid backNew debtNew shares soldNot split outChange in cash
2025-12-31-$4.99M-$518.00K$10.00K$87.77M*$82.27M
2024-12-31-$18.38M-$36.00K-$3.33M$5.00K$32.52M*$10.78M
2023-12-31-$68.62M-$486.00K-$6.67M$8.00K-$75.66M
2022-12-31-$75.72M-$1.87M$16.00K-$77.66M
2021-12-31-$80.75M-$1.10M-$1.00M$975.00K$116.36M$144.33M*$178.82M
2020-12-31-$36.09M-$2.19M$159.00K$9.87M*-$28.25M

Each quarter (3 month)

Quarter endRunning the businessFrom investingDebt paid backNew debtNew shares soldNot split outChange in cash
2026-06-30-$18.76M*-$19.00K*$0.00*$4.49M*
2026-03-31-$22.34M-$556.00K$1.00K$35.71M*$12.81M
2025-12-31-$2.00M*-$95.00K*$1.00K*$35.87M*
2025-09-30-$17.50M*$0.00*$0.00*
2025-06-30-$14.48M*-$401.00K*$4.00K*$47.36M*
2025-03-31$28.98M-$22.00K$5.00K$4.83M*$33.79M
2024-12-31-$14.16M*-$6.00K*$0.00*$0.00*$8.20M*
2024-09-30-$13.67M*-$9.00K*$0.00*$4.00K*
2024-06-30$19.95M*$0.00*$20.04M*
2024-03-31-$10.50M-$3.33M$4.29M*-$9.55M
2023-12-31-$13.43M*$0.00*-$1.67M*$0.00*
2023-09-30-$13.37M*$0.00*-$2.22M*$0.00*
2023-06-30-$16.57M*-$316.00K*-$1.11M*
2023-03-31-$25.25M-$170.00K-$1.67M-$27.11M
2022-12-31-$18.22M*-$509.00K*$0.00*
2022-09-30-$19.91M*-$333.00K*$0.00*
2022-06-30-$16.76M*-$771.00K*$0.00*
2022-03-31-$20.84M-$254.00K$16.00K-$21.09M
2021-12-31-$17.16M*-$378.00K*$0.00*$0.00*$239.00K*$115.59M*
2021-09-30-$20.72M*-$114.00K*-$667.00K*$14.00K*
2021-06-30-$20.14M*-$438.00K*$5.00K*
2021-03-31-$22.73M-$170.00K$25.00K$144.87M*$121.99M
2020-12-31-$12.71M*-$108.00K*$153.00K*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Serina Therapeutics, Inc. (SER)United States$0.054B-2.35
Clene Inc. (CLNN)United States$0.054B-1.99
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83